Q32 Bio Inc. QTTB
Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026
Q32 Bio Inc. (QTTB) is a healthcare company listed in the US with a market value of about $261M. In the twelve months to September 30, 2026 it had revenue of $54M and net income of $32M, a net margin of 60.0%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is shareholder returns (0/5).
Key numbers: a P/E of 2.5, 5-year revenue growth of 82% a year, a 5-year average ROIC of -123%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 59% below the current price.
About Q32 Bio
Q32 Bio is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. Revenue went from $5M in 2018 to $54M in 2025, growth of about 39.1% a year. It was profitable in 1 of the last 9 years in our data. Its share count rose by 3455% over three years (dilution for shareholders). It spends 36% of revenue on research and development.
Score: 2.0 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54M | $54M | $0 | $1M | $3M | $34M | $3M | $2M | $5M | — |
| Net income | $32M | $30M | -$48M | -$54M | -$5M | -$96M | -$129M | -$104M | -$56M | -$30M |
| Free cash flow | -$20M | -$34M | -$68M | -$19M | -$115M | -$112M | -$98M | -$113M | -$68M | $5M |
| EPS (diluted) | $3.47 | $2.42 | $-6.58 | $-153.96 | $-14.91 | $-286.64 | $-463.92 | $-409.25 | $-323.09 | $-2004.82 |
| Net margin | 60.0% | 55.5% | — | -4649.0% | -156.0% | -281.9% | -4762.9% | -6237.4% | -1044.3% | — |
| ROIC | — | 29.5% | -347.7% | — | — | -49.6% | -48.7% | -33.3% | -24.1% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $39.67, 355% above the current price; targets range from $29.00 to $59.00; the consensus rating is “Strong buy”; expected EPS is $-1.40 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Q32 Bio’s P/E ratio?
About 2.5, based on the last twelve months of diluted earnings per share.
Is Q32 Bio stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 59% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Q32 Bio pay a dividend?
Not currently.
Is Q32 Bio a good stock to buy?
We do not give buy or sell advice. Q32 Bio scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.